Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial - Hochhaus, A; Saglio, G; Hughes, T P (Leukemia, 2016)
, et al.